LYRA News and Press, Lyra Therapeutics Inc. From 12/07/20

Gainers: Obalon Therapeutics (OBLN) +121%.Greenland Technologies (GTEC) +79%.Oncternal Therapeutics (ONCT) +61%.Eastman Kodak (KODK) +60%.Fate Therapeutics (FATE) +46%.Nkarta (NKTX) +44%.Constellation Pharmaceuticals (CNST) +34%.Gamida Cell (GMDA) +31%.EHang Holdings (EH) +30%.Tonix...

Gainers: Obalon Therapeutics (OBLN) +116%, Oncternal Therapeutics (ONCT) +77%, Fate Therapeutics (FATE) +41%, Constellation Pharmaceuticals (CNST) +33%, Nkarta (NKTX) +28%.Losers: scPharmaceuticals (SCPH) -33%, Aptose Biosciences (APTO) -...

Lyra Therapeutics (LYRA) down 19% in premarket after announcing topline results from Phase 2 (LANTERN) study evaluating its lead candidate, LYR-210 for chronic rhinosinusitis ((CRS)),  inflammation of the sinuses and nasal cavity.Data showed that LYR-210 was not stati...

scPharmaceuticals (SCPH) -40% on complete response letter from FDA for FUROSCIX.Lyra Therapeutics, Inc. (LYRA) -28% on positive topline results for LANTERN phase 2 randomized controlled study of LYR-210 for the treatment of chronic rhinosinusitis with and without nasal polyps.A...

7500 mcg dose of LYR-210 achieved statistically significant improvement in a composite of the 4 cardinal symptoms of CRS at weeks 16 (p=0.021), 20 (p=0.012) and 24 (p=0.016) compared to control. 7500 mcg dose of LYR-210 achieved statistically significant improvement in SNO...

Gainers: Sundial Growers (SNDL) +36%, DiaMedica Therapeutics (DMAC) +20%, Aurora Cannabis ACB +19%, Lyra Therapeutics (LYRA) +19%, Tilray TLRY +10%.Losers: Medigus (MDGS) -17%, Graybug Vision (GRAY) -14%, Immunic (IMUX) -13%,&#x...

Lyra is to report top line data of its Phase 2 Trial in December. All indications are the trial should be a success, and they have strong backing from Perceptive Advisors. The market isn't paying much attention to the company at present, but good data would bring new investors. ...

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that Maria Pal...

Lyra Therapeutics (LYRA): Q3 GAAP EPS of -$0.49 misses by $0.05.Cash, cash equivalents of $81.6M.Press Release For further details see: Lyra Therapeutics EPS misses by $0.05

- On course to report topline Phase 2 LANTERN study results in December 2020 - Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatme...